Literature DB >> 21608034

Endogenous aspartoacylase expression is responsive to glutamatergic activity in vitro and in vivo.

Jeremy S Francis1, Louise Strande, Amy Pu, Paola Leone.   

Abstract

Aspartoacylase (ASPA) is an enzyme that functions to catabolize the neuronal amino acid derivative N-acetyl-L-aspartic acid (NAA). Loss of this function results in the failure of developmental myelination. NAA synthesis and catabolism are tightly compartmentalized within neurons and oligodendrocytes, respectively, and there is evidence to suggest the developmental regulation of ASPA activity is transcriptional. NAA has no known direct physiological mode of action, and the identification of a transcriptional regulator of aspa would provide an opportunity to link NAA to relatively more characterized physiological contexts with a view to definitive functional classification. Using transcriptional and immunohistochemical endpoints, we define a window of postnatal development punctuated by increases in aspa within a pre-existing population of oligodendrocytes in the rat brain. Ontological mining of expression data generated in aspa-null rats during this developmental window identifies both neuronal and oligodendroglial transcriptional abnormalities that suggest an association between glutamatergic synaptic activity and ASPA. Glutamate, but not NAA, is shown to activate endogenous aspa expression in vitro, and endogenous aspa expression is upregulated in the brains of animals over expressing vesicular glutamate transporter type-I (vglut1). These results define a discrete period of postnatal development within which glutamate provides a means by which the tightly compartmentalized NAA metabolic cycle can function in sync with normal development and may be a factor in pathological models of dysregulated NAA metabolism.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21608034     DOI: 10.1002/glia.21187

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  6 in total

1.  Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.

Authors:  Jiho Sohn; Peter Bannerman; Fuzheng Guo; Travis Burns; Laird Miers; Christopher Croteau; Naveen K Singhal; Jennifer A McDonough; David Pleasure
Journal:  J Neurosci       Date:  2017-01-11       Impact factor: 6.167

2.  Aspartoacylase supports oxidative energy metabolism during myelination.

Authors:  Jeremy S Francis; Louise Strande; Vladamir Markov; Paola Leone
Journal:  J Cereb Blood Flow Metab       Date:  2012-05-23       Impact factor: 6.200

Review 3.  A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra.

Authors:  Caroline D Rae
Journal:  Neurochem Res       Date:  2013-11-21       Impact factor: 3.996

4.  Transcriptional regulation of N-acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron-glia communication during energetic crisis.

Authors:  Samantha Zaroff; Paola Leone; Vladimir Markov; Jeremy S Francis
Journal:  Mol Cell Neurosci       Date:  2015-03-10       Impact factor: 4.314

5.  N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.

Authors:  Jeremy S Francis; Ireneusz Wojtas; Vladimir Markov; Steven J Gray; Thomas J McCown; R Jude Samulski; Larissa T Bilaniuk; Dah-Jyuu Wang; Darryl C De Vivo; Christopher G Janson; Paola Leone
Journal:  Neurobiol Dis       Date:  2016-10-04       Impact factor: 5.996

6.  Community structure analysis of transcriptional networks reveals distinct molecular pathways for early- and late-onset temporal lobe epilepsy with childhood febrile seizures.

Authors:  Carlos Alberto Moreira-Filho; Silvia Yumi Bando; Fernanda Bernardi Bertonha; Priscila Iamashita; Filipi Nascimento Silva; Luciano da Fontoura Costa; Alexandre Valotta Silva; Luiz Henrique Martins Castro; Hung-Tzu Wen
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.